Martine Rothblatt Sells 9,500 Shares of United Therapeutics (NASDAQ:UTHR) Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the business’s stock in a transaction dated Wednesday, June 17th. The shares were sold at an average price of $552.40, for a total value of $5,247,800.00. Following the sale, the chief executive officer directly owned 40,513 shares of the company’s stock, valued at approximately $22,379,381.20. This trade represents a 19.00% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

United Therapeutics Price Performance

Shares of NASDAQ:UTHR opened at $536.59 on Friday. The business has a 50-day moving average of $564.47 and a two-hundred day moving average of $523.41. The firm has a market capitalization of $22.78 billion, a PE ratio of 19.81, a P/E/G ratio of 1.75 and a beta of 0.57. United Therapeutics Corporation has a 12 month low of $272.12 and a 12 month high of $609.35.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share for the quarter, missing the consensus estimate of $7.00 by ($1.18). United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The firm had revenue of $781.50 million during the quarter, compared to analyst estimates of $797.40 million. During the same period in the prior year, the firm earned $6.63 earnings per share. The business’s revenue for the quarter was down 1.6% on a year-over-year basis. As a group, research analysts anticipate that United Therapeutics Corporation will post 26.84 earnings per share for the current year.

Analysts Set New Price Targets

UTHR has been the topic of a number of recent research reports. Morgan Stanley set a $516.00 price target on shares of United Therapeutics in a research report on Thursday, May 7th. Weiss Ratings reissued a “buy (b)” rating on shares of United Therapeutics in a research report on Thursday, June 11th. Royal Bank Of Canada cut their target price on shares of United Therapeutics from $707.00 to $701.00 and set an “outperform” rating on the stock in a research note on Thursday, May 7th. Jefferies Financial Group restated a “buy” rating on shares of United Therapeutics in a report on Monday, March 2nd. Finally, Bank of America upped their price target on shares of United Therapeutics from $569.00 to $626.00 and gave the stock a “neutral” rating in a research report on Tuesday, March 31st. Eleven equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $619.42.

Institutional Investors Weigh In On United Therapeutics

Several hedge funds have recently modified their holdings of the stock. Torren Management LLC acquired a new position in United Therapeutics during the 4th quarter worth approximately $26,000. Activest Wealth Management grew its position in United Therapeutics by 1,400.0% in the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock valued at $29,000 after acquiring an additional 56 shares in the last quarter. Entrust Financial LLC acquired a new stake in United Therapeutics in the fourth quarter valued at approximately $31,000. International Assets Investment Management LLC raised its stake in shares of United Therapeutics by 426.7% during the first quarter. International Assets Investment Management LLC now owns 79 shares of the biotechnology company’s stock valued at $45,000 after purchasing an additional 64 shares during the period. Finally, Wilmington Savings Fund Society FSB raised its stake in shares of United Therapeutics by 125.6% during the third quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock valued at $37,000 after purchasing an additional 49 shares during the period. 94.08% of the stock is currently owned by hedge funds and other institutional investors.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.